A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Status:
Completed
Trial end date:
2021-09-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of
study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736
in combination with olaparib and bevacizumab (module 6). It will also examine what happens to
the study drugs in the body and investigate how well the combination between MEDI4736,
olaparib and bevacizumab is tolerated.